NOV 22, 2017
Glaucoma, Medical Therapy, Surgical Management
In this interview from AAO 2017, Dr. Jeffrey Goldberg highlights current research on preventing vision loss in glaucoma patients through neuroprotection of retinal ganglion cells (RGCs). Dr. Goldberg refers to the importance of a "belt and suspenders approach", wherein pressure controlling medications and devices are complemented by new therapies that directly enhance the function of RGCs or optic nerve fibers.
Relevant Financial Disclosures: Dr. Goldberg is a consultant for Annexon, Inotek, Johnson & Johnson, Aerie, Alcon, Novartis, and Allergan. He receives grant support from the National Institutes of Health, Department of Defense, and Glaucoma Research Foundation.